I pick out North America’s celestial highlights for the week ahead (which also applies to northern hemisphere mid-northern latitudes).
Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a metallo-beta-lactamase (MBL) inhibitor that helps reduce resistance to beta-lactam antibiotics such as meropenem.
"This early-stage introduction of MET-X into the Indian market leverages our decades-long dedication to AMR-focused R&D and our prominent role in critical care and antibiotic ther
Publisher Koei Tecmo and developer Team NINJA have released a new trailer, information, and screenshots for Venus Vacation PRISM: DEAD OR ALIVE Xtreme, introducing the collaboration episodes with
The agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, an innovative metallo-beta- lactamase (MBL) inhibitor
The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. Currently, there are no approved MBL inhibitors available in the country.
Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to tackle drug-resistant gram-negative bacteria in India. The partnership aims to address the growing concern of antibiotic resistance and provide effective treatment options for patients.